Company Filing History:
Years Active: 2019-2023
Title: Robyn Puro: Innovator in Therapeutic Antibodies
Introduction
Robyn Puro is a notable inventor based in St. Louis, MO (US), recognized for his contributions to the field of therapeutic antibodies. With a total of four patents to his name, Puro has made significant strides in developing innovative treatments for various diseases.
Latest Patents
Among his latest patents are the Therapeutic CD47 antibodies, which include anti-CD47 monoclonal antibodies (anti-CD47 mAbs) with distinct functional profiles. These antibodies are designed for use in the prevention and treatment of solid and hematological cancers, ischemia-reperfusion injury, cardiovascular diseases, autoimmune diseases, and inflammatory diseases. Additionally, they serve as diagnostics for determining the level of CD47 in tissue samples. Another significant patent is for Therapeutic SIRP-α antibodies, which encompass anti-SIRP-α monoclonal antibodies (anti-SIRP-α mAbs) and multispecific SIRP-α antibodies. These are also aimed at treating solid and hematological cancers, with detailed amino acid sequences provided for exemplary anti-SIRP-α monoclonal antibodies.
Career Highlights
Robyn Puro is currently associated with Arch Oncology, Inc., where he continues to advance his research and development efforts in the field of therapeutic antibodies. His work is pivotal in addressing critical health challenges through innovative solutions.
Collaborations
Puro collaborates with esteemed colleagues, including Juan C Almagro and Pamela T Manning, who contribute to the research and development of therapeutic antibodies.
Conclusion
Robyn Puro's innovative work in therapeutic antibodies positions him as a key figure in the medical research community. His patents reflect a commitment to improving treatment options for serious health conditions.